Bechtel Medical announced on Tuesday that its Wound VOX advanced therapy system has received 510(k) premarket clearance from the US Food and Drug Administration. Wound care technology takes a leap forward. The innovative medical device represents the first cleared platform that combines negative pressure wound therapy with adjunctive topical oxygen therapy. It addresses complex clinical challenges in treating chronic diabetic ulcers and post-surgical wounds.
Traditional clinical protocols often require separate devices and frequent dressing disruptions to deliver negative pressure and localized oxygen. "Integrating negative pressure drainage and topical oxygen into a single system simplifies delivery and lowers healthcare costs," said chief executive John Gvodas. The unified hardware architecture alleviates operational burdens on hospital nursing staff and specialized wound clinics. Streamlined therapy protocols reduce patient discomfort during extended outpatient recovery.
The Wound VOX console features three programmable operational modes: continuous negative pressure, intermittent pressure, and combined intermittent pressure with topical oxygen. "Clinical trials demonstrate that dual-action therapy achieves superior complete wound closure rates and reduces bacterial contamination," medical researchers reported. Delivering targeted topical oxygen directly stimulates cellular granulation and enhances localized capillary revascularization. The therapy significantly mitigates tissue hypoxia in poorly vascularized chronic lesions.
Bechtel Medical plans a phased commercial launch across selected US health networks in December 2026 before nationwide expansion. Millions of elderly patients living with venous leg ulcers and non-healing pressure injuries stand to benefit from the integrated system. Combining distinct therapeutic modalities within a portable bedside console represents an important advancement in outpatient chronic care. The clearance marks a major step forward for specialized regenerative wound care.
